Insight Molecular Diagnostics Inc (IMDX) Stock Price, Quote & News

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 949 409 7600

Website: imdxinc.com

Address:

2 International Plaza Dr., Suite 510, Nashville, United States

Bogwood Oct. 22 at 9:48 PM

$IMDX This opportunity continues to be incredibly reflexive as they will need another financing by 2H26. Josh and Andrea have done a great job evangelizing and executing this year

1 · Reply

RUNNINWILD Oct. 22 at 7:06 PM

$IMDX beast

0 · Reply

JohnPDaly Oct. 22 at 2:34 PM

$LCTX $MDWD $IMDX “A sword-day, a red day, ere the sun rises!" J.R.R. Tolkien's The Lord of the Rings.

1 · Reply

RUNNINWILD Oct. 22 at 1:27 AM

$IMDX

0 · Reply

cache1b Oct. 21 at 11:05 PM

$IMDX @JohnPDaly Congrats... That truck driving thru the spread was bringing medical relief. I know, cuz I got some. It's a chronic condition, looking for less pain, and more gain. Please keep it coming. @LefDeppard

0 · Reply

_www_larval_com_ Oct. 21 at 7:52 PM

$JWEL -6%[23%] $IMDX 5%[10%] $QH -4%[15%] $SLGB -4%[12%] $RANI -3%[31%] most notable movement into the final minutes of trading.

0 · Reply

RUNNINWILD Oct. 21 at 2:08 PM

$IMDX broadwood owns approximately 40% BioRad approx 10%

0 · Reply

jackedmund99 Oct. 21 at 2:05 PM

$IMDX obviously there’s a complete reevaluation of this company going on right now somebody you know out there realizes that this company has a bigger potential in the market cap indicates currently and that’s why they’re bidding the stock up. Anyone who has a Cell is getting taken out, I threw a few few shares out there just to test the waters and they were quickly grabbed something serious is happening.

1 · Reply

NY2CHI Oct. 20 at 5:01 PM

$IMDX been on a straight tear. Can’t wait till fda approves this device next year. Then 🌕

0 · Reply

JohnPDaly Oct. 17 at 6:46 PM

$IMDX once again, as the only one here, I would like to congratulate me. Well, done.

3 · Reply

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch

Oct 6, 2025, 7:15 AM EDT - 19 days ago

iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset' with Novel Therapy and GraftAssure Monitoring

Sep 24, 2025, 7:05 AM EDT - 4 weeks ago

Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Sep 8, 2025, 7:15 AM EDT - 6 weeks ago

Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database

Sep 8, 2025, 7:00 AM EDT - 6 weeks ago

IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants

Aug 26, 2025, 4:05 PM EDT - 2 months ago

iMDx to Participate in NYC Investment Conferences September 8 - 11

Aug 11, 2025, 4:05 PM EDT - 2 months ago

IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch

Aug 4, 2025, 4:05 PM EDT - 2 months ago

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

Jul 30, 2025, 4:05 PM EDT - 3 months ago

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

Jul 28, 2025, 4:05 PM EDT - 3 months ago

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

Jun 23, 2025, 4:05 PM EDT - 4 months ago

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

Jun 17, 2025, 7:00 AM EDT - 4 months ago

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

May 19, 2025, 4:05 PM EDT - 5 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 12, 2025, 11:32 PM EDT - 5 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 5 months ago

Oncocyte Reports Q1 2025 Results and Business Progress

May 7, 2025, 4:10 PM EDT - 6 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

Apr 30, 2025, 8:30 AM EDT - 6 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 29, 2025, 8:30 AM EDT - 6 months ago

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Mar 24, 2025, 6:53 PM EDT - 7 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 4:05 PM EDT - 7 months ago

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Feb 11, 2025, 8:30 AM EST - 9 months ago

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 8, 2025, 8:30 AM EST - 10 months ago

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Jan 6, 2025, 4:05 PM EST - 10 months ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Nov 12, 2024, 8:52 PM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:45 PM EST - 1 year ago

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oct 16, 2024, 4:15 PM EDT - 1 year ago

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Jun 24, 2024, 12:41 PM EDT - 1 year ago

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

May 30, 2024, 4:47 PM EDT - 1 year ago

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results

Apr 9, 2024, 4:05 PM EDT - 1 year ago

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Jul 25, 2023, 9:08 AM EDT - 2 years ago

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test

Jun 1, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Corporation to Present at the LD Micro Invitational XIII

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 2 years ago

Oncocyte To Announce First Quarter 2023 Financial Results

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Oncocyte Presents New Data at AACR

Apr 12, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Announces Reduction in Force

Apr 7, 2023, 8:24 AM EDT - 2 years ago

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

Apr 3, 2023, 11:40 AM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Mar 31, 2023, 5:00 PM EDT - 2 years ago

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 9:00 AM EST - 2 years ago

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

Bogwood Oct. 22 at 9:48 PM

$IMDX This opportunity continues to be incredibly reflexive as they will need another financing by 2H26. Josh and Andrea have done a great job evangelizing and executing this year

1 · Reply

RUNNINWILD Oct. 22 at 7:06 PM

$IMDX beast

0 · Reply

JohnPDaly Oct. 22 at 2:34 PM

$LCTX $MDWD $IMDX “A sword-day, a red day, ere the sun rises!" J.R.R. Tolkien's The Lord of the Rings.

1 · Reply

RUNNINWILD Oct. 22 at 1:27 AM

$IMDX

0 · Reply

cache1b Oct. 21 at 11:05 PM

0 · Reply

_www_larval_com_ Oct. 21 at 7:52 PM

$JWEL -6%[23%] $IMDX 5%[10%] $QH -4%[15%] $SLGB -4%[12%] $RANI -3%[31%] most notable movement into the final minutes of trading.

0 · Reply

RUNNINWILD Oct. 21 at 2:08 PM

$IMDX broadwood owns approximately 40% BioRad approx 10%

0 · Reply

jackedmund99 Oct. 21 at 2:05 PM

1 · Reply

NY2CHI Oct. 20 at 5:01 PM

$IMDX been on a straight tear. Can’t wait till fda approves this device next year. Then 🌕

0 · Reply

JohnPDaly Oct. 17 at 6:46 PM

$IMDX once again, as the only one here, I would like to congratulate me. Well, done.

3 · Reply

jackedmund99 Oct. 17 at 3:26 PM

$IMDX I own over 100,000 shares at a cost near 240 been here for a while obviously some sophisticated money is coming into the stock as they know what’s about to happen with new oncology tests addressing a billion dollar market -Market cap is still micro

1 · Reply

JohnPDaly Oct. 16 at 6:32 PM

$IMDX 🎃💰🎃

0 · Reply

jackedmund99 Oct. 16 at 6:17 PM

$IMDX gotta love the slow steady move I’m looking at his reevaluating the value of this company as it starts to rip up sales in $1 billion marketplace if they get a fraction of that business it deserves to be more than $200 million market especially with all the other products they got going on so that implies at least 87 to 8 dollars

1 · Reply

jackedmund99 Oct. 16 at 3:51 PM

$IMDX stock moving towards new high in very tight hands small market cap going after billion dollar markets - I like the odds !

0 · Reply

JohnPDaly Oct. 15 at 5:49 PM

$IMDX 🎃🍁💰

0 · Reply

JohnPDaly Oct. 15 at 2:38 PM

$IMDX Looking more like a winner every day.

0 · Reply

RUNNINWILD Oct. 14 at 7:58 PM

$IMDX it’s difficult to accumulate any significant amount of shares because it just pushes up the stock price by entering the buy orders

2 · Reply

jackedmund99 Oct. 14 at 7:21 PM

$IMDX about time they start reconsidering the possibilities that ste now available

1 · Reply

JohnPDaly Oct. 13 at 8:14 PM

iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2025/10-13-2025-210530881

0 · Reply

jackedmund99 Oct. 8 at 12:22 PM

$IMDX https://www.linkedin.com/posts/andreajames123_imdx-reports-kidney-transplant-patient-achieved-activity-7380995959973076992-fPb6?utm_medium=ios_app&rcm=ACoAAAGTUQEBIAend-uSLhvmiDbarslxama_K3o&utm_source=social_share_send&utm_campaign=copy_link

0 · Reply

NY2CHI Oct. 7 at 8:14 PM

$IMDX starter position in this as of this am.

1 · Reply

topstockalerts Oct. 6 at 2:14 PM

Insight Molecular Diagnostics shares rose Monday after the company reported study results published in the American Journal of Transplantation showing the effectiveness of its GraftAssure test in monitoring a kidney transplant patient with severe complications. The study described a 33-year-old transplant recipient who developed lymphoma but maintained stable graft function for about two years without immunosuppression while undergoing novel CD19 CAR-T therapy. Insight’s GraftAssure molecular test confirmed the absence of organ rejection throughout treatment. Chief Scientific Officer Dr. Ekke Schuetz said the case highlights the reliability of the company’s dd-cfDNA assay in rare clinical settings and noted that as transplant care incorporates new immunomodulatory therapies like CAR-T, the need for molecular monitoring will keep growing. $IMDX

0 · Reply

Market Cap	189.75M
Revenue (ttm)	1.88M
Net Income (ttm)	-60.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,226.60%
Debt to Equity Ratio	0.00

Volume	65,100
Avg Vol	49,844
Day's Range	N/A - N/A
Shares Out	28.62M
Stochastic %K	96%
Beta	1.24
Analysts	Sell
Price Target	$5.42